Development of an ELISpot Assay for the Assessment of AAV Peptides to Examine Immune Safety

Sara Krivoshik,Lindsey Dzielak,April R Masters,Jennifer Hall,Alison J Johnson

DOI: https://doi.org/10.1089/hum.2023.180

2024-01-25

Human Gene Therapy

Abstract:Adeno-associated virus (AAV)-based gene therapies have shown promise as novel treatments for rare genetic disorders such as Haemophilia A and Spinal Muscular Atrophy. However, cellular immune responses mediated by cytotoxic (CD8+) and helper (CD4+) T cells may target vector-transduced cells as well as healthy immune cells, impacting safety and efficacy. Here, we describe the optimization and reproducibility of interferon-γ (IFNγ)- and interleukin-2 (IL-2)-based Enzyme-Linked Immunosorbent Spot (ELISpot) assays for measuring T cell responses against AAV peptide antigens. For method optimization, peripheral blood mononuclear cells (PBMCs) were isolated from healthy human donors and stimulated with commercially available major histocompatibility complex (MHC) class I or II specific peptides as positive controls. Peptide pools were designed from published AAV8 and AAV9 capsid protein sequences and then used to assess the presence of AAV-specific T cell responses. Our results demonstrate a measurable increase in IFNγ and IL-2-producing cells after AAV peptide presentation. Furthermore, there was an observed difference in the magnitude and specificity of response to peptide pools based on AAV serotype and donor. Finally, using individual peptides, we identified a region of the AAV9 capsid protein that can elicit an immunogenic response. This work shows the applicability of ELISpot in assessing anti-AAV immune responses and provides insight into how novel recombinant AAV vectors could be designed to reduce immunogenic potential.

genetics & heredity,medicine, research & experimental,biotechnology & applied microbiology